1. Dong, S.*, Mani, R.*, Orwick, S., Walker, A., Wasmuth, R.L., Behbehani, G., Chang, H., Deodato, C., Byrd., J.C. (2018) Entosplentinib is effective in MLL-rearranged Acute Myeloid Leukemia. In preparation. (*equal contribution)
2. Murali, I., Kasar, S., McWilliams, S., Tyekucheva, S., Livitz, D., Leshchiner, I., Dong, S., Fernandes, S., Itchaki, G., Getz, G., Johnson, A.J., Brown J.R. (2018) Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia. In preparation.
3. Paz, K., Flynn, R., Du, J., Tannheimer, S., Johnson, A.J., Dong, S., Stark, A.K., Okkenhaug, K., Panoskaltsis-Mortari, A., Sage, P.T., Sharpe, A.H., Luznik, L., Ritz, J., Soiffer, R.J., Cutler, C.S., Koreth, J., Antin, J.H., Miklos, D.B., MacDonald, K.P., Hill, G.R., Maillard, I., Serody, J.S., Munn, D.H., Feser, C., Zaiken, M., Vanhaesebroeck, B., Turka, L.A., Byrd, J.C., Blazar, B.R. (2018) Targeting PI3Kδ Function For Amelioration of Murine Chronic Graft-Versus-Host Disease. In submission to Leukemia.
4. Mitchell, S., Larkin, K., Grieselhuber, N., Lai, T., Cannon, M., Orwick, S., Sharma, P., Asemelash, Y., Zhang, P., Goettel, M.V., Beaver, L., Mim, A., Puduvalli, V., Blachly, J.S., Lehman, A.M., Harrington, B.K., Henderson, S., Breitbach, J.T., Williams, K.E., Dong, S., Baloglu, E., Senapedis, W., Kirschner, K., Sampath D., Lapalombella, R., Byrd, J.C. (2018) Selective Targeting of NAMPT by KPT-9274 in Acute Myeloid Leukemia. In revision at Blood Advances.
5. Dong, S., Harrington, B.K., Hu, E.Y., Greene, J.T., Lehman, A.M., Tran, M., Wasmuth, R.L., Long, M., Muthusamy, N., Brown, J.R., Johnson, A.J., Byrd, J.C. (2018) PI3K p110δ inactivation antagonizes Chronic Lymphocytic Leukemia and reverses T-cell immune suppression. Accepted by Journal of Clinical Investigation.
6. Dong, S., Byrd, J.C., (2016) A New Role for Lyn in the CLL Microenvironment. Cancer Cell.10;30(4):511-512.
7. Liu, T.-M., Woyach, J.A., Zhong, Y., Lozanski, A., Lozanski, G., Dong, S., Strattan, E., Lehman, A., Zhang, X., Jones, J., Flynn, J., Andritsos, L., Maddocks, K., Jaglowski, S., Blum, K., Byrd, J.C., Dubovsky, J.A., and Johnson, A.J. (2015). Hypermorphic mutation of phospholipase C, gamma 2 acquired in ibrutinib resistant CLL confers BTK independency upon BCR activation. Blood, 126(1), 61-8
8. Zhong, Y., Dong, S., Strattan, E., Ren, L., Butchar, J.P., Thornton, K., Mishra, A., Porcu, P., Bradshaw, M., Bisconte, A., Owens, T.D., Verner, E., Brameld, K.A., Funk, J.O., Hill, R.J., Johnson, A.J., Dubovsky, J.A. (2014). Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694. Journal of Biological Chemistry, 2015 290: 10568-10569.
9. Dong, S.*, Guinn, D.*, Dubovsky, J.A., Zhong, Y., Lehman, A., Kutok, J., Woyach, J.A., Byrd, J.C., Johnson, A.J. (2014). IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood, 124(24), 3583-6 (*equal contribution)
10. Dong, S., Zhao, Y., Liu, H., Yang, X., Wang, K., (2009). Duality of effect of La3+ on mitochondrial permeability transition pore depending on the concentration. Biometals, 22(6), 917-26